サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753205

スターガルト病治療薬の世界市場

Stargardt Disease Therapeutics

出版日
ページ情報
英文 364 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.80円
スターガルト病治療薬の世界市場
出版日: 2025年06月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 364 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

スターガルト病治療薬の世界市場は2030年までに19億米ドルに達する見込み

2024年に3億6,010万米ドルと推定されるスターガルト病治療薬の世界市場は、分析期間2024-2030年にCAGR 31.7%で成長し、2030年には19億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるEmixustatは、CAGR 33.9%を記録し、分析期間終了時には12億米ドルに達すると予測されます。LBS-008セグメントの成長率は、分析期間でCAGR 29.1％と推定されます。

米国市場は9,810万米ドルと推定、中国はCAGR 41.5％で成長予測

米国のスターガルト病治療薬市場は、2024年に9,810万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRが41.5％で、2030年には4億8,600万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ25.4％と28.7％と予測されています。欧州では、ドイツがCAGR約26.9%で成長すると予測されています。

世界のスターガルト病治療薬市場- 主要動向と促進要因まとめ

スターガルト病が研究開発で注目される理由

スターガルト病は、遺伝性黄斑変性症の中で最も一般的な疾患であり、主に小児や若年成人が罹患します。ABCA4遺伝子の変異によって引き起こされ、網膜色素上皮（RPE）細胞におけるリポフスチンの蓄積により、中心視力の進行性喪失を引き起こします。この蓄積は光受容体を損傷し、最終的に黄斑萎縮と法定失明に至る。遺伝性網膜疾患の中でも有病率が高いにもかかわらず、現在のところ承認された治療法はなく、重大なアンメット・メディカル・ニーズとなっています。

スターガルト病の分子的・遺伝的基盤に対する理解が深まりつつあり、薬剤開発、遺伝子治療、再生医療への取り組みが活発化しています。自家蛍光や光干渉断層計（OCT）などの画像診断の進歩は、治療効果の評価に不可欠な早期発見と疾患モニタリングを容易にしています。患者登録が拡大し、希少疾病に対する規制上の優遇措置が強化されるにつれて、スターガルト病は眼科治療薬の標的を開発する企業にとって焦点となりつつあります。

どのような新しいアプローチがスターガート病管理の将来を形作るのか？

ABCA4の機能的発現を回復させることを目的とした遺伝子置換療法など、いくつかの治験的治療法が開発中です。網膜下への遺伝子導入にはAAV（アデノ随伴ウイルス）ベクターが一般的に使用されているが、遺伝子サイズが大きいことが重要な課題となっており、デュアルベクターや非ウイルス導入アプローチへの関心が高まっています。視覚サイクル調節薬であるEmixustatや、リポフスチン形成を抑制する他の低分子阻害薬も臨床試験を進行中です。

幹細胞療法は、視力を維持したり損傷した細胞を置き換えたりするために、胚性幹細胞や人工多能性幹細胞（iPSC）由来のRPE細胞を網膜に移植する再生アプローチとして支持を集めています。さらに、CRISPRに基づく遺伝子編集やアンチセンス・オリゴヌクレオチド（ASO）が、ABCA4変異の修正や疾患経路の修正を目的として研究されています。これらの次世代プラットフォームは、特に早期の患者において、長期的な疾患修飾に対する楽観論を後押ししています。

臨床および地域情勢別で、治療開発はどこで進んでいるのか？

治療開発は、北米と欧州の主要な研究機関が主要な試験を実施し、学術、バイオテクノロジー、製薬の共同研究によって推進されています。臨床試験は、網膜専門医、遺伝カウンセラー、患者支援団体の世界のネットワークを通じて調整され、多様な患者集団をリクルートしています。FDAとEMAは複数のパイプライン候補に希少疾病用医薬品の指定を与え、迅速な承認と市場独占権の延長を可能にしています。

地域的には、北米がスターガルト臨床研究の最も進んだ市場であり、強力な制度的枠組みと患者登録に支えられています。欧州は、学術主導の遺伝子治療研究と産業界のパートナーシップの両方が活発です。アジア太平洋では、特に日本と韓国で関心が高まり始めており、眼科の技術革新と希少疾患への資金援助が増加しています。遺伝子スクリーニングがより利用しやすくなるにつれて、世界的に患者の特定と試験登録の拡大が予想されます。

スターガルト病治療薬市場の世界的成長の原動力は？

スターガルト病治療薬市場の世界の成長は、遺伝子診断率の上昇、遺伝性網膜疾患に対する意識の高まり、遺伝子ベースの治療法の加速度的な進化によってもたらされます。この疾患の希少性は、高い臨床ニーズと長期的な社会的影響によって相殺されており、スターガルト病は眼科用医薬品開発パイプラインの中で戦略的焦点として位置づけられています。

公的・私的資金、規制上の優遇措置、患者擁護の高まりが一体となって技術革新を加速させています。治療情勢が精密医療とゲノム介入へとシフトする中、スターガルト病は網膜変性症におけるトランスレーショナル・リサーチの有望なモデルとなっています。複数の第Ⅱ相および第Ⅲ相臨床試験が進行中であり、新規の市場開拓技術も開発中であることから、スターガルト病治療薬の世界市場は今後10年間で大きな進展を遂げる準備が整っています。

セグメント

薬剤タイプ（エミクススタット、LBS-008、その他の薬剤タイプ）、年齢層（17歳未満、17歳以上）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（計34社に注目）

  • 4P-Pharma
  • Alkeus Pharmaceuticals
  • Ascidian Therapeutics
  • Astellas Pharma
  • Belite Bio
  • Biophytis
  • Clearside Biomedical
  • Gene Vector Technologies
  • IVERIC bio
  • Kiora Pharmaceuticals
  • Kubota Vision
  • MD Stem Cells
  • Mediphage Bioceuticals
  • Nanoscope Therapeutics
  • Novartis
  • Ocugen
  • Oxford Biomedica
  • reVision Therapeutics
  • SalioGen Therapeutics
  • SpliceBio

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35819

Global Stargardt Disease Therapeutics Market to Reach US$1.9 Billion by 2030

The global market for Stargardt Disease Therapeutics estimated at US$360.1 Million in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 31.7% over the analysis period 2024-2030. Emixustat, one of the segments analyzed in the report, is expected to record a 33.9% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the LBS-008 segment is estimated at 29.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$98.1 Million While China is Forecast to Grow at 41.5% CAGR

The Stargardt Disease Therapeutics market in the U.S. is estimated at US$98.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$486.0 Million by the year 2030 trailing a CAGR of 41.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 25.4% and 28.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 26.9% CAGR.

Global Stargardt Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Is Stargardt Disease Drawing Increased Research and Therapeutic Development Attention?

Stargardt disease is the most common form of inherited macular degeneration, primarily affecting children and young adults. Caused by mutations in the ABCA4 gene, it leads to progressive loss of central vision due to lipofuscin accumulation in retinal pigment epithelium (RPE) cells. This accumulation damages photoreceptors, ultimately resulting in macular atrophy and legal blindness. Despite its prevalence among inherited retinal disorders, no approved treatment currently exists, making it a significant unmet medical need.

Growing understanding of the molecular and genetic basis of Stargardt disease is stimulating drug development, gene therapy, and regenerative medicine efforts. Advances in imaging diagnostics-such as autofluorescence and optical coherence tomography (OCT)-are facilitating early detection and disease monitoring, essential for assessing therapeutic efficacy. As patient registries expand and regulatory incentives for orphan diseases intensify, Stargardt disease is becoming a focal point for companies developing targeted ophthalmic therapeutics.

What Novel Approaches Are Shaping the Future of Stargardt Disease Management?

Several investigational therapies are under development, including gene replacement therapies aimed at restoring functional ABCA4 expression. AAV (adeno-associated virus) vectors are commonly used for subretinal gene delivery, though large gene size remains a key challenge-prompting interest in dual-vector or non-viral delivery approaches. Emixustat, a visual cycle modulator, and other small molecule inhibitors that reduce lipofuscin formation are also progressing through clinical trials.

Stem cell therapies are gaining traction as a regenerative approach, wherein RPE cells derived from embryonic or induced pluripotent stem cells (iPSCs) are transplanted into the retina to preserve vision or replace damaged cells. Additionally, CRISPR-based gene editing and antisense oligonucleotides (ASOs) are being explored to correct ABCA4 mutations or modify disease pathways. These next-generation platforms are driving optimism for long-term disease modification, especially in early-stage patients.

Where Is Therapeutic Development Advancing Across Clinical and Geographic Landscapes?

Therapeutic development is being driven by a mix of academic, biotech, and pharmaceutical collaborations, with leading institutions in North America and Europe conducting pivotal studies. Clinical trials are being coordinated through global networks of retinal specialists, genetic counselors, and patient advocacy groups to recruit diverse patient populations. The FDA and EMA have granted orphan drug designations to multiple pipeline candidates, enabling fast-track approvals and extended market exclusivity.

In terms of geography, North America represents the most advanced market for Stargardt clinical research, supported by strong institutional frameworks and patient registries. Europe is active in both academic-led gene therapy studies and industrial partnerships. Asia-Pacific is beginning to see emerging interest, particularly in Japan and South Korea, where ophthalmic innovation and rare disease funding are increasing. As genetic screening becomes more accessible, broader patient identification and trial enrollment are expected globally.

What’s Driving the Global Growth of the Stargardt Disease Therapeutics Market?

The growth in the global Stargardt disease therapeutics market is driven by increasing genetic diagnosis rates, rising awareness of inherited retinal diseases, and the accelerated evolution of gene-based treatments. The rarity of the condition is counterbalanced by high clinical need and long-term societal impact, positioning Stargardt disease as a strategic focus within ophthalmic drug development pipelines.

Public and private funding, regulatory incentives, and growing patient advocacy are collectively accelerating innovation. As the therapeutic landscape shifts toward precision medicine and genomic intervention, Stargardt disease represents a promising model for translational research in retinal degeneration. With multiple Phase II and III trials underway and novel delivery technologies in development, the global market for Stargardt disease therapeutics is poised for substantial progress in the coming decade.

SCOPE OF STUDY:

The report analyzes the Stargardt Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Emixustat, LBS-008, Other Drug Types); Age Group (Below 17 Years, Above 17 Years); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • 4P-Pharma
  • Alkeus Pharmaceuticals
  • Ascidian Therapeutics
  • Astellas Pharma
  • Belite Bio
  • Biophytis
  • Clearside Biomedical
  • Gene Vector Technologies
  • IVERIC bio
  • Kiora Pharmaceuticals
  • Kubota Vision
  • MD Stem Cells
  • Mediphage Bioceuticals
  • Nanoscope Therapeutics
  • Novartis
  • Ocugen
  • Oxford Biomedica
  • reVision Therapeutics
  • SalioGen Therapeutics
  • SpliceBio

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Stargardt Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Inherited Retinal Diseases Propels Research and Investment in Stargardt Therapeutics
    • Expansion of Orphan Drug Designation Programs Throws the Spotlight on Regulatory Incentives for Rare Disease Drugs
    • Innovation in Gene Therapy Vectors and Delivery Platforms Accelerates Breakthrough Treatment Options
    • Growth in Public and Private Genomic Research Funding Strengthens Early-Stage Clinical Pipelines
    • Development of Lipid-Based and AAV-Mediated Delivery Systems Enhances Retinal Cell Uptake
    • Increasing Use of Patient-Derived Stem Cells for In Vitro Disease Modeling Expands Drug Discovery Potential
    • Focus on CRISPR-Based Editing and RPE65-Targeted Therapies Improves Mutation-Specific Efficacy
    • Surge in FDA Fast Track and Breakthrough Therapy Approvals Shortens Development Timelines
    • Participation in International Clinical Trial Networks Enhances Trial Recruitment and Data Diversity
    • Expansion of Imaging Biomarkers and AI-Based Retinal Analysis Tools Strengthens Diagnostic Accuracy
    • Entry Into RNA-Based and Antisense Oligonucleotide Therapies Drives Mechanism Diversity
    • Rising Patient Advocacy and Awareness Campaigns Fuel Clinical Trial Enrollment and Policy Support
    • Advances in Target Validation and Small Molecule Screening Accelerate Pipeline Progression
    • Increasing Focus on Pediatric and Early-Onset Stargardt Variants Expands Treatment Windows
    • Collaboration With Academic Institutions and CROs Enhances Translational Research Efficiency
    • Growth in Cell-Based Therapies and Encapsulated Cell Technologies Creates Opportunities for Localized Delivery
    • Differentiation Through Safety, Durability, and Visual Acuity Restoration Metrics Enhances Clinical Outcomes
    • Surge in Strategic Licensing and M&A Activity Reflects Commercial Interest in Inherited Retinal Therapeutics
    • Investment in Companion Diagnostics and Genetic Counseling Infrastructure Strengthens Market Readiness
    • Global Push for Rare Disease Solutions and Targeted Ocular Therapies Sustains Investment in Stargardt Disease Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stargardt Disease Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stargardt Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Stargardt Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Emixustat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Emixustat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Emixustat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for LBS-008 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for LBS-008 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for LBS-008 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Below 17 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Below 17 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Below 17 Years by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Above 17 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Above 17 Years by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Above 17 Years by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Stargardt Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Stargardt Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Stargardt Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Stargardt Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Stargardt Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Stargardt Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Stargardt Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Stargardt Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Stargardt Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Stargardt Disease Therapeutics by Drug Type - Emixustat, LBS-008 and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Stargardt Disease Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Emixustat, LBS-008 and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Stargardt Disease Therapeutics by Age Group - Below 17 Years and Above 17 Years Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Stargardt Disease Therapeutics by Age Group - Percentage Breakdown of Value Sales for Below 17 Years and Above 17 Years for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Stargardt Disease Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Stargardt Disease Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION